entertainment -WSS

entertainment

author：fashion 2025-08-28 03:35:03 - browse：2

Monica Bertagnolli -- Health Policy coverage from STAT — Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Attacks on the drug industry will lead to fewer breakthroughs

explore

WSS

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Readout LOUD podcast: Live from the 2023 STAT Summit

CZI to create biohub to build anti

Merck, Daiichi strike cancer drug pact worth up to $22 billion

What Mike Pence has said that could be used in a Donald Trump trial

STAT Summit: Ending the crisis of Black deaths in the U.S.

entertainment

entertainment

Sign up for D.C. Diagnosis

knowledge

What does generative AI mean for health care? We asked experts

What the cancer research community can learn from the Covid response

Jerome Adams on the need for new antivirals for Covid

Why a market frenzy over new weight loss drugs defies logic

Alkermes shareholders re

Biden calls for immediate release of Niger's president amid apparent coup

Hepatitis C has a cure — but many Americans still lack access to it

Results on Novartis prostate cancer therapy could expand its use

Medicare details structure of new drug price negotiation program

ProMED, early warning system on disease outbreaks, in peril

hotspot

'Ancient DNA,' 23andMe reveal African American ancestries

My superpower is killing ticks

STAT Readout Newsletter: Biotech news today

UnitedHealth, Optum discontinue NaviHealth name

STAT Summit: How researchers deal with rejection

The problems with dementia villages

leisure time

explore

explore

knowledge